COMETRIQ™ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
COMETRIQ™ inhibits the activity of tyrosine kinases in vitro including RET, MET, and VEGFRs. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
COMETRIQ™ is exclusively distributed by Diplomat Specialty Pharmacy, which may be contacted at:
Learn more about Exelixis® Access Services, a unique program that provides information on MTC patient access to COMETRIQ™, reimbursement support, and financial assistance.